One weeks treatment with the long acting GLP-1 derivative, NN2211, markedsly increases 24-h glycaemia, reduces endogenous glucose release and improves alfa- and beta-cell function in type 2 diabetes patients
Year: 2004
Type: article
Authors: Degn, Kirstine Bruun, Juhl, C.B., Sturis, J., Jakobsen, B., Chandramouli, V., Rungby, Jørgen, Landau, B.R., O., Schmitz
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7042395442